Investment adviser · CRD 161150

PHARMAKON ADVISORS, LP

Investment adviser filing (IA)

NEW YORK, NY, United States · Form ADV filed Mar 31, 2026

Regulatory AUM: $3.04B
Client accounts: 5
Employees: 15
Advisory professionals: 9

Who they report serving

Form ADV · Item 5.D

Client types and their share of reported regulatory assets.

Client type	Clients	Regulatory assets	Share of AUM
Pooled investment vehicles	4	$1,870,085,438	61.5%
Other clients	1	$1,168,274,661	38.5%

Filing source

Form ADV 2085189 · Mar 31, 2026 · Item 5.D

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

Private funds & service providers

9 Private funds

The count excludes feeder funds. Funds in the latest filing appear first, ordered by reported gross assets. Earlier funds retain their last reported values.

BIOPHARMA CREDIT INVESTMENTS V (MASTER) LPPrivate Equity Fund · Last reported Mar 31, 2026$1.87BGross asset value

Feeder funds

Fund administrator HEDGESERV (CAYMAN) LTD GEORGE TOWN, Cayman Islands Investor statements: Some (provided to some but not all investors) Related to adviser: No

Auditor ERNST & YOUNG LLP DUBLIN 2, Ireland

Custodian COMPUTERSHARE TRUST COMPANY, N.A. ST. PAUL, Minnesota, United States Related to adviser: No

Custodian NORTHERN TRUST INTERNATIONAL BANKING CORPORATION JERSEY CITY, New Jersey, United States Related to adviser: No

Marketer MIZUHO SECURITIES CO. LTD. TOKYO, Japan Related to adviser: No

Provider details

Annual audit: Yes
Prime brokers: No
Custodians: Yes
Administrator other than the adviser: Yes
External marketing: Yes

ERNST & YOUNG LLP
PCAOB 1411

Fund details & source

Fund ID: 805-2616755366
Reported beneficial owners: 171
Minimum commitment: $0
Form D file number: 021-342013
Form D file number: 021-342354
Form D file number: 021-395258

Form ADV 2085189 · Mar 31, 2026 · Schedule D 7.B.(1)

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

BIOPHARMA SECURED INVESTMENTS III SARLPrivate Equity Fund · Last reported Jun 13, 2017$345MGross asset value

Form D fundraising filings

BioPharma Secured Investments III, S.ar.l

Fund administrator INTERTRUST LUXEMBOURG L-2453 LUXEMBOURG, Luxembourg Investor statements: Some (provided to some but not all investors) Related to adviser: No

Auditor ERNST & YOUNG LLP DUBLIN 2, Ireland

Custodian BANK OF AMERICA DALLAS, Texas, United States Related to adviser: No

Custodian THE ROYAL BANK OF SCOTLAND L-1012, Luxembourg Related to adviser: No

Marketer GROTON SECURITIES LLC NEW YORK, New York, United States Related to adviser: No

Marketer VIER KLEEBLATT INVESTMENT AG ZURICH, Switzerland Related to adviser: No

Provider details

Annual audit: Yes
Prime brokers: No
Custodians: Yes
Administrator other than the adviser: Yes
External marketing: Yes

GROTON SECURITIES LLC
CRD 126600 · SEC 8-65896

Fund details & source

Fund ID: 805-1253180070
Reported beneficial owners: 76
Minimum commitment: $0
Form D file number: 021-199818

Form ADV 1113667 · Jun 13, 2017 · Schedule D 7.B.(1)

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

BIOPHARMA SECURED INVESTMENTS II, SARLPrivate Equity Fund · Last reported Jun 13, 2017$138MGross asset value

Form D fundraising filings

BioPharma Secured Debt Fund II, S. ar. l.

Fund administrator INTERTRUST LUXEMBOURG L-2453 LUXEMBOURG, Luxembourg Investor statements: Some (provided to some but not all investors) Related to adviser: No

Auditor ERNST & YOUNG LLP DUBLIN, Ireland

Custodian BANK OF AMERICA DALLAS, Texas, United States Related to adviser: No

Custodian THE ROYAL BANK OF SCOTLAND L-1012 LUXEMBOURG, Luxembourg Related to adviser: No

Marketer GROTON SECURITIES LLC NEW YORK, New York, United States Related to adviser: No

Marketer VIER KLEEBLATT INVESTMENT AG ZURICH, Switzerland Related to adviser: No

Provider details

Annual audit: Yes
Prime brokers: No
Custodians: Yes
Administrator other than the adviser: Yes
External marketing: Yes

GROTON SECURITIES LLC
CRD 126600 · SEC 8-65896

Fund details & source

Fund ID: 805-3130153519
Reported beneficial owners: 51
Minimum commitment: $0
Form D file number: 021-157021

Form ADV 1113667 · Jun 13, 2017 · Schedule D 7.B.(1)

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

PHARMAKON OPPORTUNITIES LPPrivate Equity Fund · Last reported Apr 12, 2019$46.5MGross asset value

Auditor PRICEWATERHOUSECOOPERS LLP NEW YORK, New York, United States

Custodian BANK OF AMERICA DALLAS, Texas, United States Related to adviser: No

Provider details

Annual audit: Yes
Prime brokers: No
Custodians: Yes
Administrator other than the adviser: No
External marketing: No

PRICEWATERHOUSECOOPERS LLP
PCAOB 238

Fund details & source

Fund ID: 805-8622676619
Reported beneficial owners: 12
Minimum commitment: $0

Form ADV 1309950 · Apr 12, 2019 · Schedule D 7.B.(1)

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

BIOPHARMA SECURED DEBT FUND, LPPrivate Equity Fund · Last reported May 1, 2014$29.9MGross asset value

Feeder funds

Auditor ERNST & YOUNG LLP DUBLIN 2, Ireland

Custodian BANK OF AMERICA CHICAGO, Illinois, United States Related to adviser: No

Marketer DAVID RITZ DALLAS, Texas, United States Related to adviser: No

Marketer VIER KLEEBLATT INVESTMENT AG ZURICH, Switzerland Related to adviser: No

Provider details

Annual audit: Yes
Prime brokers: No
Custodians: Yes
Administrator other than the adviser: No
External marketing: Yes

Fund details & source

Fund ID: 805-5363562642
Reported beneficial owners: 58
Minimum commitment: $0
Form D file number: 021-132649
Form D file number: 021-173487

Form ADV 822375 · May 1, 2014 · Schedule D 7.B.(1)

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LPPrivate Equity Fund · Last reported Apr 12, 2019$16.7MGross asset value

Auditor ERNST & YOUNG LLP DUBLIN 2, Ireland

Custodian BANK OF AMERICA DALLAS, Texas, United States Related to adviser: No

Provider details

Annual audit: Yes
Prime brokers: No
Custodians: Yes
Administrator other than the adviser: No
External marketing: No

ERNST & YOUNG LLP
PCAOB 1411

Fund details & source

Fund ID: 805-4802502769
Reported beneficial owners: 2
Minimum commitment: $0

Form ADV 1309950 · Apr 12, 2019 · Schedule D 7.B.(1)

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

BIOPHARMA SECURED INVESTMENTS III PARTNERS, LPPrivate Equity Fund · Last reported Apr 12, 2019$11.8MGross asset value

Auditor ERNST & YOUNG LLP DUBLIN 2, Ireland

Custodian BANK OF AMERICA DALLAS, Texas, United States Related to adviser: No

Marketer 2M MANAGEMENT, LLC NEW YORK, New York, United States Related to adviser: No

Marketer VIER KLEEBLATT INVESTMENT AG ZURICH, Switzerland Related to adviser: No

Provider details

Annual audit: Yes
Prime brokers: No
Custodians: Yes
Administrator other than the adviser: No
External marketing: Yes

ERNST & YOUNG LLP
PCAOB 1411

Fund details & source

Fund ID: 805-7826269271
Reported beneficial owners: 31
Minimum commitment: $0

Form ADV 1309950 · Apr 12, 2019 · Schedule D 7.B.(1)

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

Services & filing details

Most recent filing: Mar 31, 2026. View historical filings

Reported services

Pooled investment vehicle management

Compensation

Percentage of assets · Performance-based

Principal office

110 EAST 59TH STREET, 28TH FLOOR
NEW YORK, NY, 10022-1304, United States

CRD 161150

Filing source

Form ADV 2085189 · Mar 31, 2026 · Items 1 & 5

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.